PROGNOSTIC AND PREDICTIVE VALUE OF ANDROGEN RECEPTOR EXPRESSION IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR–POSITIVE BREAST CANCER.
The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60-80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic […]
